Cargando…
Safety and efficacy of cyclooxygenase-2 inhibition for treatment of primary hypertrophic osteoarthropathy: A single-arm intervention trial
BACKGROUND: Primary hypertrophic osteoarthropathy (PHO) is a rare disease involving joint, bone and skin. Two underlying genes responsible for this disease—hydroxyprostaglandin dehydrogenase (HPGD) and solute carrier organic anion transporter family, member 2A1 (SLCO2A1)—are both associated with abe...
Autores principales: | Yuan, Lu, Liao, Ruo-xi, Lin, Yuan-yuan, Jiang, Yan, Wang, Ou, Li, Mei, Xing, Xiao-ping, Pang, Qian-qian, Hsieh, Evelyn, Xia, Wei-bo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Chinese Speaking Orthopaedic Society
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718875/ https://www.ncbi.nlm.nih.gov/pubmed/31508314 http://dx.doi.org/10.1016/j.jot.2018.10.001 |
Ejemplares similares
-
Hypertrophic osteoarthropathy
por: Wang, Gang, et al.
Publicado: (2023) -
Hypertrophic Osteoarthropathy
por: Kojima, Hiroki, et al.
Publicado: (2022) -
Hypertrophic pulmonary osteoarthropathy with primary lung cancer
por: QIAN, XINYU, et al.
Publicado: (2014) -
Primary Hypertrophic Osteoarthropathy With Myelofibrosis
por: Yousaf, Muhammad, et al.
Publicado: (2022) -
The first case of primary hypertrophic osteoarthropathy with soft tissue giant tumors caused by HPGD loss-of-function mutation
por: Pang, Qianqian, et al.
Publicado: (2019)